drugset / Trial / NCT01040130

Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I

NCT01040130

Phase 3 Completed 151 enrolled Boehringer Ingelheim
RandomizedCrossoverDouble-blindTreatment

Summary

To compare the effects of BI 1744 CL versus placebo on exercise tolerance after 6 weeks of treatment in patients with Chronic Obstructive Pulmonary Disease

Timeline

Start
2010-01
Primary completion
2011-04
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Olodaterol Small molecule 5 ug Inhaled
Subject Olodaterol Small molecule 10 ug Inhaled